Last updated: Sep 9, 2026 · Built by a patient who got tired of scrolling ClinicalTrials.gov
Active interventional trials with status RECRUITING or NOT_YET_RECRUITING. A multi-phase trial (e.g. 1/2) is counted in each of its phases.
Biomarkers, stage, prior treatments — get a ranked shortlist in minutes.
Recruiting trials grouped by drug class. Trials with unclassifiable or non-therapeutic interventions are excluded from this view.
| NCT | Phase | Title | Mechanism |
|---|---|---|---|
| NCT06064097 | 2 | A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC) | PD-1 -- immune checkpoint inhibitor (monoclonal antibody) |
| NCT07667400 | 1, 2 | Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer | CXCR1/2 -- small molecule antagonist (chemokine receptor inhibitor) |
| NCT06029270 | 2 | Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer | LAG-3 -- immune checkpoint inhibitor (monoclonal antibody) |
| NCT07625423 | 1 | Intratumoral Injection of Recombinant Human Endostatin Adenovirus (EDS01) for the Treatment of Recurrent or Metastatic Head and Neck Tumors | VEGF -- angiogenesis inhibitor via recombinant human endostatin gene delivery (gene therapy) |
| NCT06980038 | 2 | Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer | PD-1 + CD40 -- immune checkpoint blockade and CD40 agonist (monoclonal antibodies) |
| Sponsor | Recruiting trials |
|---|---|
| Sun Yat-sen University | 73 |
| Fujian Cancer Hospital | 9 |
| Fudan University | 9 |
| Zhejiang Cancer Hospital | 6 |
| Jiangxi Provincial Cancer Hospital | 6 |
Countries/regions with the most active trial sites for nasopharyngeal carcinoma. A multi-site trial is counted once per country/region.
Phase-1 trials whose listed start date falls within the last 12 months — the leading edge of the field.
| Start | NCT | Title | Mechanism |
|---|---|---|---|
| Sep 9, 2026 | NCT07667400 | Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer | CXCR1/2 -- small molecule antagonist (chemokine receptor inhibitor) |
| Sep 2026 | NCT07650266 | A Study of Cemiplimab and Fianlimab in People With Nasopharyngeal Carcinoma | PD-1 + CTLA-4 -- bispecific antibody |
| Apr 2026 | NCT07247201 | Integrating Allogeneic NK Cells in High-risk Advanced Stage III-IV Nasopharyngeal Cancer Patients | Natural Killer cells -- adoptive cell therapy |
| Mar 31, 2026 | NCT07320963 | Chidamide in Combination With Toripalimab and Anlotinib in Recurrent/Metastatic Nasopharyngeal Carcinoma. | HDAC + PD-1 + VEGFR -- HDAC inhibitor + immune checkpoint inhibitor + multi-kinase inhibitor |
| Mar 27, 2026 | NCT07625423 | Intratumoral Injection of Recombinant Human Endostatin Adenovirus (EDS01) for the Treatment of Recurrent or Metastatic Head and Neck Tumors | VEGF -- angiogenesis inhibitor via recombinant human endostatin gene delivery (gene therapy) |
You've seen the nasopharyngeal carcinoma landscape. Now find the trials that fit your case.
Enter biomarkers, stage, and prior treatments — get ranked matches with eligibility breakdown in minutes.
Find My Matches →Source: ClinicalTrials.gov, synced daily. Aggregated by ClinTrialFinder.